Anti‐Viral Treatment Eligibility and Treatment Uptake Among People With Chronic Hepatitis B in Australia: The REACH ‐B Study
Journal of Viral Hepatitis · 2026-12 · 33 (12)
DOI: 10.1111/jvh.70238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 02.11.2026. Verfasst von Behzad Hajarizadeh und 28 weiteren Autor:innen. Beteiligte Einrichtung: The Kirby Institute, University of New South Wales (UNSW), Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Antiviral Agents. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Health and Aged Care, Australian Government, National Health and Medical Research Council of Australia (NHMRC) Investigator Grants, Robert W. Storr Bequest to the Sydney Medical Foundation, The University of Sydney.
Abstract (Originalsprache)
Treatment indication for chronic hepatitis B (CHB) varies across clinical guidelines. This study evaluated treatment eligibility and uptake in a large Australian cohort of people with CHB. The REACH‐B study recruited people with CHB managed through a national network of healthcare services. Participants were categorised into three groups: (1) receiving antiviral therapy; (2) untreated despite eligibility; (3) untreated and ineligible. Treatment eligibility was determined using Australian Pharmaceutical Benefits Scheme (PBS) criteria, and by international clinical guidelines. Among 3648 participants (56% male; median age 48 years; 49% born in North‐East or South‐East Asia; 27% First Nations Australians), 14% were HBeAg positive and 7% had cirrhosis. Overall, 47% ( n = 1666) were on antiviral therapy, 45% ( n = 1573) were untreated and ineligible and 7% ( n = 251) were untreated despite eligibility based on Australian PBS criteria. In adjusted analysis, the likelihood of remaining untreated despite eligibility was higher among women (aOR 1.59, 95% CI 1.34, 1.88) and younger participants (age 41–60 vs. > 60 years: aOR 1.51, 95% CI 1.01–2.28; ≤ 40 vs. > 60 years: aOR 2.65, 95% CI 1.60, 4.40). The proportion untreated despite eligibility increased to 13% when applying 2024 World Health Organisation guidelines and ranged 2%–44% based on other guidelines, highlighting the variability across the guidelines. In conclusion, among REACH‐B participants, most eligible individuals receive treatment. Lower treatment uptake among women and younger people despite eligibility partly reflects lower threshold for elevated ALT in women, and clinician determination of non‐CHB related ALT elevation. As treatment guidelines evolve and eligibility criteria broaden, monitoring treatment patterns is important.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Kirby Institute, University of New South Wales (UNSW), Sydney, New South Wales, Australia.
- The Queen Elizabeth Hospital and Royal Adelaide Hospital, Adelaide, South Australia, Australia.
- Storr Liver Centre, Westmead Hospital, and The Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.
- Cairns and Hinterland Hospital and Health Service, and Torres and Cape Hospital and Health Service, Cairns, Queensland, Australia.
- Menzies School of Health Research, Darwin, Northern Territory, Australia.
- Justice Health and Forensic Mental Health Network NSW, Sydney, New South Wales, Australia.
ORCID-Profile: Behzad Hajarizadeh, Renjy Nelson, Jacob George, Josh Hanson, Marianne Martinello, Tracey Brown, Tasnim Hasan, Lester Mascarenhas, James O'Beirne, Amanda Wade, Sarah Thomas, Benjamin Cowie, Nicole Allard, Thomas Tu, Lien Tran, Jessica Carter, Elise Tu, Joanne Carson, Gregory J Dore
Förderung
- Department of Health and Aged Care, Australian Government
- National Health and Medical Research Council of Australia (NHMRC) Investigator Grants
- Robert W. Storr Bequest to the Sydney Medical Foundation, The University of Sydney
- NHMRC Program Grants
- MRFF grants
- Cancer Institute NSW grant
- The Paul and Valeria Ainsworth Precision Medicine Fellowship
- GESA 2025 Lawrie Powell AC Mid-Career Grant
Zitieren
APA
Hajarizadeh, B., Nelson, R., George, J., Hanson, J., Davies, J., Martinello, M., Brown, T., Wong, I., Hasan, T., Mascarenhas, L., O'Beirne, J., Wade, A., Capati, M., Trotter, G., Thomas, S., Nash, L., Cowie, B., Allard, N., Tu, T., …, & REACH‐B Study Group (2026). Anti‐Viral Treatment Eligibility and Treatment Uptake Among People With Chronic Hepatitis B in Australia: The REACH ‐B Study. Journal of Viral Hepatitis, 33(12). https://doi.org/10.1111/jvh.70238
Vancouver
Hajarizadeh B, Nelson R, George J, Hanson J, Davies J, Martinello M, et al. Anti‐Viral Treatment Eligibility and Treatment Uptake Among People With Chronic Hepatitis B in Australia: The REACH ‐B Study. Journal of Viral Hepatitis. 2026;33(12). doi:10.1111/jvh.70238
BibTeX
@article{Hajarizadeh2026,
author = {Hajarizadeh, Behzad and Nelson, Renjy and George, Jacob and Hanson, Josh and Davies, Jane and Martinello, Marianne and Brown, Tracey and Wong, Ian and Hasan, Tasnim and Mascarenhas, Lester and O'Beirne, James and Wade, Amanda and Capati, Marilou and Trotter, Georgina and Thomas, Sarah and Nash, Lloyd and Cowie, Benjamin and Allard, Nicole and Tu, Thomas and Tran, Lien and Howard, Stephanie and Monaghan, Robert and Carter, Jessica and Tu, Elise and Erratt, Amanda and Carson, Joanne and Dore, Gregory J and Matthews, Gail V and REACH‐B Study Group, REACH‐B Study Group},
title = {Anti‐Viral Treatment Eligibility and Treatment Uptake Among People With Chronic Hepatitis B in Australia: The REACH ‐B Study},
journal = {Journal of Viral Hepatitis},
year = {2026},
volume = {33},
number = {12},
doi = {10.1111/jvh.70238}
}
EUVIMED